{
  "report_rows": [
    {
      "kpi": "Adjusted diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$3.18 vs. cons $3.142",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$4.92B vs. cons $4.890B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "BioPharma Systems revenue",
      "prediction": "BEAT",
      "answer": "pred ~$650M vs. cons $637M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 adjusted EPS",
      "prediction": "BETTER",
      "answer": "guide ~$12.65\u2013$12.85 vs. cons $12.61",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 organic revenue growth",
      "prediction": "UNCHANGED",
      "answer": "guide low-single-digit vs. cons 2.51%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 adjusted operating margin",
      "prediction": "UNCHANGED",
      "answer": "guide approximately 25% vs. cons UNVERIFIED",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 3.0,
  "day1_confidence": "LOW",
  "day5_residual_pct": 2.0,
  "day5_path": "STABILIZE",
  "day5_rationale": "STABILIZE \u2014 real Q4 EPS upside, moderated by a demanding stock setup",
  "day5_confidence": "LOW"
}